Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.50 Consensus Price Target from Analysts

Gain Therapeutics, Inc. (NASDAQ:GANX) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $8.50.

GANX has been the subject of several analyst reports. Roth Mkm reissued a “buy” rating on shares of Gain Therapeutics in a report on Tuesday, May 12th. Oppenheimer reissued an “outperform” rating on shares of Gain Therapeutics in a report on Wednesday, May 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Gain Therapeutics in a report on Friday, April 10th.

Gain Therapeutics Price Performance

Shares of GANX opened at $1.70 on Monday. Gain Therapeutics has a fifty-two week low of $1.41 and a fifty-two week high of $4.34. The company has a market capitalization of $72.51 million, a price-to-earnings ratio of -2.93 and a beta of 0.16. The firm has a 50-day simple moving average of $1.86 and a 200-day simple moving average of $2.34. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.69 and a current ratio of 4.69.

Gain Therapeutics (NASDAQ:GANX) last announced its earnings results on Monday, May 11th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). During the same quarter last year, the company posted ($0.16) EPS. On average, equities research analysts anticipate that Gain Therapeutics will post -0.54 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC purchased a new position in Gain Therapeutics during the third quarter worth about $28,000. Sprott Inc. purchased a new position in Gain Therapeutics during the fourth quarter worth about $39,000. Commonwealth Equity Services LLC purchased a new position in Gain Therapeutics during the fourth quarter worth about $41,000. Millennium Management LLC purchased a new position in Gain Therapeutics during the fourth quarter worth about $45,000. Finally, JPMorgan Chase & Co. purchased a new position in Gain Therapeutics during the third quarter worth about $47,000. 11.97% of the stock is owned by hedge funds and other institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.